Advertisement

Current Transplantation Reports

, Volume 6, Issue 2, pp 109–118 | Cite as

Cell Therapy: Past, Present, and Future

  • Morgan Hamon
  • Peter V. HauserEmail author
Cellular Transplants (G Orlando, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Cellular Transplants

Abstract

Purpose of Review

Cellular therapy started in the early twentieth century with the development of blood transfusion and later bone marrow transplantation. This review describes the historical origins and major milestones in the field of cellular therapy. We discuss ethical concerns associated with certain cell sources and how they influenced therapy strategies. A focus of this article is on the use of stem cells to understand regenerative repair after kidney injury. In addition, we give an overview over past and current kidney-related cellular therapy trials.

Recent Findings

The number of kidney-related cellular therapy trials has been growing exponentially over the last 20 years. Main applications of kidney-related cellular therapy are in renal cancer and kidney transplant tolerance. The USA and China are the countries with the highest number of cellular therapy trials.

Summary

Cellular therapy, in combination with the recent advances in iPS cell generation and CRISPR-Cas 9, has a bright future. It has the potential to enable highly personalized therapy strategies to overcome problems associated with cancer therapy, transplant rejection, and organ regeneration.

Keywords

Regenerative medicine Kidney disease Renal clinical trial Current trends 

Notes

Funding Information

MH and PVH would like to thank Prof. Norimoto Yanagawa, MD and the Chau-Li Foundation (to N.Y.) for financial support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Nathoo N, Lautzenheiser FK, Barnett GH. The first direct human blood transfusion: the forgotten legacy of George W. Crile. Neurosurgery. 2009;64:ons20–6 discussions 26-27.Google Scholar
  2. 2.
    Carrel A. On the permanent life of tissue outside of the organism. J Exp Med. 1912;15:516–28.CrossRefGoogle Scholar
  3. 3.
    U.S. Congress, Office of Technology Assessment. Unconventional Cancer Treatments. Washington DC: Government Printing Office; 1990.Google Scholar
  4. 4.
    Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell. 2008;3:591–4.CrossRefGoogle Scholar
  5. 5.
    • Murdoch B, Zarzeczny A, Caulfield T. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites’ marketing of stem cell therapies. BMJ Open. 2018;8:e019414. This analysis demonstrates how scientific language is used to promote unfounded claims in the marketing of stem cell therapies. CrossRefGoogle Scholar
  6. 6.
    Thomas ED. Bone marrow transplantation from the personal viewpoint. Int J Hematol. 2005;81:89–93.CrossRefGoogle Scholar
  7. 7.
    U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products [Internet]. FDA; 2018 [cited 2018 Aug 12]. Available from: https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/default.htm. Accessed 29 Sep 2018
  8. 8.
    Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–22.CrossRefGoogle Scholar
  9. 9.
    Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000;18:399–404.CrossRefGoogle Scholar
  10. 10.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–7.CrossRefGoogle Scholar
  11. 11.
    Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634–8.CrossRefGoogle Scholar
  12. 12.
    Doetschman T, Williams P, Maeda N. Establishment of hamster blastocyst-derived embryonic stem (ES) cells. Dev Biol. 1988;127:224–7.CrossRefGoogle Scholar
  13. 13.
    Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Becker RA, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 1995;92:7844–8.CrossRefGoogle Scholar
  14. 14.
    Bongso A, Fong CY, Ng SC, Ratnam S. Isolation and culture of inner cell mass cells from human blastocysts. Hum Reprod. 1994;9:2110–7.CrossRefGoogle Scholar
  15. 15.
    Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J. 2003;4:92–6.CrossRefGoogle Scholar
  16. 16.
    Mosna F, Sensebé L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user’s guide. Stem Cells Dev. 2010;19:1449–70.CrossRefGoogle Scholar
  17. 17.
    Bieback K, Klüter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther. 2007;2:310–23.CrossRefGoogle Scholar
  18. 18.
    Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice. Kidney Int. 2005;68:1940–3.CrossRefGoogle Scholar
  19. 19.
    Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–9.CrossRefGoogle Scholar
  20. 20.
    Yao T, Asayama Y. Animal-cell culture media: history, characteristics, and current issues. Reprod Med Biol. 2017;16:99–117.CrossRefGoogle Scholar
  21. 21.
    Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefGoogle Scholar
  22. 22.
    • Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262–78. This article reviews the development and applications of the CRISPR-associated endonuclease Cas9 as a platform technology for achieving targeted perturbation of endogenous genomic elements and also discuss challenges and future avenues for innovation. CrossRefGoogle Scholar
  23. 23.
    Little MH. Regrow or repair: potential regenerative therapies for the kidney. J Am Soc Nephrol. 2006;17:2390–401.CrossRefGoogle Scholar
  24. 24.
    •• Guidelines for Stem Cell Research and Clinical Translation [Internet]. ISSCR; 2016. Available from: http://www.isscr.org/docs/default-source/all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-research-and-clinical-translationd67119731dff6ddbb37cff0000940c19.pdf?sfvrsn=4. Accessed 29 Sep 2018. Guidelines from the International Society for Stem Cell Research that covers aspects of stem cell research (the ethical considerations, the laboratory-based research, the clinical applications), communications (with policy makers, the popular press, and popular culture), and regulatory standards.
  25. 25.
    Gertow K, Wolbank S, Rozell B, Sugars R, Andäng M, Parish CL, et al. Organized development from human embryonic stem cells after injection into immunodeficient mice. Stem Cells Dev. 2004;13:421–35.CrossRefGoogle Scholar
  26. 26.
    Ben-Hur T, Idelson M, Khaner H, Pera M, Reinhartz E, Itzik A, et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells. 2004;22:1246–55.CrossRefGoogle Scholar
  27. 27.
    Toyohara T, Mae S-I, Sueta S-I, Inoue T, Yamagishi Y, Kawamoto T, et al. Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice. Stem Cells Transl Med. 2015;4:980–92.CrossRefGoogle Scholar
  28. 28.
    Rufaihah AJ, Huang NF, Jamé S, Lee JC, Nguyen HN, Byers B, et al. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2011;31:e72–9.CrossRefGoogle Scholar
  29. 29.
    Tögel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol. 2007;292:F1626–35.CrossRefGoogle Scholar
  30. 30.
    Choi SJ, Kim JK, Hwang SD. Mesenchymal stem cell therapy for chronic renal failure. Expert Opin Biol Ther. 2010;10:1217–26.CrossRefGoogle Scholar
  31. 31.
    Dhar D, Hsi-en Ho J. Stem cell research policies around the world. Yale J Biol Med. 2009;82:113–5.Google Scholar
  32. 32.
    Kellathur SN, Lou H-X. Cell and tissue therapy regulation: worldwide status and harmonization. Biologicals. 2012;40:222–4.CrossRefGoogle Scholar
  33. 33.
    Gottweis H, Prainsack B. Emotion in political discourse: contrasting approaches to stem cell governance in the USA, UK, Israel and Germany. Regen Med. 2006;1:823–9.CrossRefGoogle Scholar
  34. 34.
    Meyer JR. The significance of induced pluripotent stem cells for basic research and clinical therapy. J Med Ethics. 2008;34:849–51.CrossRefGoogle Scholar
  35. 35.
    Mathews DJH, Donovan PJ, Harris J, Lovell-Badge R, Savulescu J, Faden R. Pluripotent stem cell-derived gametes: truth and (potential) consequences. Cell Stem Cell. 2009;5:11–4.CrossRefGoogle Scholar
  36. 36.
    Nussbaum J, Minami E, Laflamme MA, Virag JAI, Ware CB, Masino A, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007;21:1345–57.CrossRefGoogle Scholar
  37. 37.
    Dressel R, Schindehütte J, Kuhlmann T, Elsner L, Novota P, Baier PC, et al. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients’ immune response. PLoS One. 2008;3:e2622.CrossRefGoogle Scholar
  38. 38.
    Yamashita T, Kawai H, Tian F, Ohta Y, Abe K. Tumorigenic development of induced pluripotent stem cells in ischemic mouse brain. Cell Transplant. 2011;20:883–91.CrossRefGoogle Scholar
  39. 39.
    Yasuda S, Kusakawa S, Kuroda T, Miura T, Tano K, Takada N, et al. Tumorigenicity-associated characteristics of human iPS cell lines. PLoS One. 2018;13:e0205022.CrossRefGoogle Scholar
  40. 40.
    Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110:1362–9.CrossRefGoogle Scholar
  41. 41.
    Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16:35–52.CrossRefGoogle Scholar
  42. 42.
    Wang Y, Liu J, Jiang Q, Deng J, Xu F, Chen X, et al. Human adipose-derived mesenchymal stem cell-secreted CXCL1 and CXCL8 facilitate breast tumor growth by promoting angiogenesis. Stem Cells. 2017;35:2060–70.CrossRefGoogle Scholar
  43. 43.
    Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y, Tanaka S, et al. Mesenchymal stem cells induce epithelial to mesenchymal transition in colon cancer cells through direct cell-to-cell contact. Neoplasia. 2017;19:429–38.CrossRefGoogle Scholar
  44. 44.
    Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N. Tumor-activated mesenchymal stromal cells promote osteosarcoma xstemness and migratory potential via IL-6 secretion. PLoS One. 2016;11:e0166500.CrossRefGoogle Scholar
  45. 45.
    Berger M, Muraro M, Fagioli F, Ferrari S. Osteosarcoma derived from donor stem cells carrying the Norrie’s disease gene. N Engl J Med. 2008;359:2502–4.CrossRefGoogle Scholar
  46. 46.
    Qian H, Ding X, Zhang J, Mao F, Sun Z, Jia H, et al. Cancer stemness and metastatic potential of the novel tumor cell line K3: an inner mutated cell of bone marrow-derived mesenchymal stem cells. Oncotarget. 2017;8:39522–33.Google Scholar
  47. 47.
    •• Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10:740–9. This review presents a practitioner's perspective on the challenges and technical barriers that must be overcome for novel stem cell therapies to achieve meaningful clinical impact. It includes an interesting comparison between past and present methodologies for stem cell research and how modern research learned from the history of the hematopoietic stem cell transplantation. CrossRefGoogle Scholar
  48. 48.
    • Caulfield T, Rachul C, Zarzeczny A. The evolution of policy issues in stem cell research: an international survey. Stem Cell Rev. 2012;8:1037–42 This survey provides useful insight into the perception of how key policy issues were becoming more or less contentious over time, and suggest that although traditional debates, such as those surrounding the moral status of the embryo, remain, other issues are becoming increasingly contentious, especially those more closely associated with clinical translation and commercialization.CrossRefGoogle Scholar
  49. 49.
    Regenberg AC, Hutchinson LA, Schanker B, Mathews DJH. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells. 2009;27:2312–9.CrossRefGoogle Scholar
  50. 50.
    Cyranoski D. Stem-cell therapy takes off in Texas. Nature. 2012;483:13–4.CrossRefGoogle Scholar
  51. 51.
    Bianco P, Barker R, Brüstle O, Cattaneo E, Clevers H, Daley GQ, et al. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J. 2013;32:1489–95.CrossRefGoogle Scholar
  52. 52.
    Munsie M, Lysaght T, Hendl T, Tan H-YL, Kerridge I, Stewart C. Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan. Regen Med. 2017;12:777–90.CrossRefGoogle Scholar
  53. 53.
    •• Rial-Sebbag E, Blasimme A. The European court of human rights’ ruling on unproven stem cell therapies: a missed opportunity. Stem Cells Dev. 2014;23(Suppl 1):39–43. Description of the legal proceedings regarding a patient’s claim to access to cellular therapy with unproven efficasy that was rejected by the court. CrossRefGoogle Scholar
  54. 54.
    U.S. Renal Data System. USRDS 2017 Annual Data Report: Epidemiology of kidney disease in the United States. [Internet]. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017. Available from: https://www.usrds.org. Accessed 29 Sep 2018
  55. 55.
    Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol. 2001;195:229–35.CrossRefGoogle Scholar
  56. 56.
    Maeshima A, Yamashita S, Nojima Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J Am Soc Nephrol. 2003;14:3138–46.CrossRefGoogle Scholar
  57. 57.
    Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. J Clin Invest. 2004;114:795–804.CrossRefGoogle Scholar
  58. 58.
    Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005;166:545–55.CrossRefGoogle Scholar
  59. 59.
    Bussolati B, Hauser PV, Carvalhosa R, Camussi G. Contribution of stem cells to kidney repair. Curr Stem Cell Res Ther. 2009;4:2–8.CrossRefGoogle Scholar
  60. 60.
    Gupta S, Verfaillie C, Chmielewski D, Kim Y, Rosenberg ME. A role for extrarenal cells in the regeneration following acute renal failure. Kidney Int. 2002;62:1285–90.CrossRefGoogle Scholar
  61. 61.
    Imasawa T, Utsunomiya Y, Kawamura T, Zhong Y, Nagasawa R, Okabe M, et al. The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol. 2001;12:1401–9.Google Scholar
  62. 62.
    Lin F, Cordes K, Li L, Hood L, Couser WG, Shankland SJ, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol. 2003;14:1188–99.CrossRefGoogle Scholar
  63. 63.
    Humphreys BD, Valerius MT, Kobayashi A, Mugford JW, Soeung S, Duffield JS, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell. 2008;2:284–91.CrossRefGoogle Scholar
  64. 64.
    Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14:1035–41.Google Scholar
  65. 65.
    Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol. 2004;15:1794–804.CrossRefGoogle Scholar
  66. 66.
    Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005;289:F31–42.CrossRefGoogle Scholar
  67. 67.
    • Grange C, Iampietro C, Bussolati B. Stem cell extracellular vesicles and kidney injury. Stem Cell Investig. 2017;4:90. This article provides an overview about the potential of extracellular vesicles for renal regeneration as an alternative for cellular therapy. CrossRefGoogle Scholar
  68. 68.
    Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053–67.CrossRefGoogle Scholar
  69. 69.
    Lv L-L, Wu W-J, Feng Y, Li Z-L, Tang T-T, Liu B-C. Therapeutic application of extracellular vesicles in kidney disease: promises and challenges. J Cell Mol Med. 2018;22:728–37.CrossRefGoogle Scholar
  70. 70.
    Ikarashi K, Li B, Suwa M, Kawamura K, Morioka T, Yao J, et al. Bone marrow cells contribute to regeneration of damaged glomerular endothelial cells. Kidney Int. 2005;67:1925–33.CrossRefGoogle Scholar
  71. 71.
    Cornacchia F, Fornoni A, Plati AR, Thomas A, Wang Y, Inverardi L, et al. Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. J Clin Invest. 2001;108:1649–56.CrossRefGoogle Scholar
  72. 72.
    Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells. 2006;24:2448–55.CrossRefGoogle Scholar
  73. 73.
    Hauser PV, De Fazio R, Bruno S, Sdei S, Grange C, Bussolati B, et al. Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol. 2010;177:2011–21.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Renal Regeneration LaboratoryVAGLAHS at SepulvedaNorth HillsUSA
  2. 2.David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  3. 3.Department of Integrative Biology and PhysiologyUniversity of California at Los AngelesLos AngelesUSA

Personalised recommendations